Here Technologies is a company that provides mapping and location data and related services to individuals and companies. It is majority-owned by a consortium of German automotive companies, whilst other companies own minority stakes, its roots date back to U. S.-based Navteq in 1985, acquired by Finland-based Nokia in 2007. Here is based in Amsterdam. Here captures location content such as road networks, buildings and traffic patterns, it sells or licenses that mapping content, along with map related navigation and location services to other businesses such as Alpine, Garmin, BMW, Oracle and Amazon.com. In addition, Here provides platform services to smartphones, it provides location services through its own Here applications, for GIS and government clients and other providers, such as Bing and Yahoo! Maps. Here has maps of nearly 200 countries, offers voice guided navigation in 94 countries, provides live traffic information in 33 countries and has indoor maps available for about 49,000 unique buildings in 45 countries.
The company is working on self-driving technology. Here has built its location business by acquiring location technology. Navteq was an American company founded in 1985 as Karlin & Collins, Inc. known as Navigation Technologies Corporation and as Navteq. At the time of its acquisition by Nokia, Navteq was the largest maker of automotive-grade map data used in car navigation equipment. Nokia Maps began in 2001 as Smart2Go, a generic 3D-map interface for access to tourist information on mobile terminals, it was developed by an EU consortium named TellMaris. Nokia gained the rights to the software when it acquired Berlin-based route planning software company Gate 5 in August 2006, which has become the cornerstone for the company's mapping business, it made the Smart2Go application free to download. In October 2007, Nokia acquired Navteq, which brought 25 years of experience in creating automotive grade map content, a deep footprint in the automotive industry. Nokia ran Navteq's business along with their own Nokia Maps.
The two divisions remained as separate entities of Nokia Corporation until Navteq was amalgamated into the core Nokia operations in 2011. The service was rebranded as HERE in 2012, bringing together mapping, location businesses, satellite navigation and other services under one brand. In 2008, Nokia picked up geosocial networking site Plazes and the following year it bought mobile applications developer Bit-Side, social location pioneer Plum, social travel service Dopplr. In 2010, it acquired MetaCarta a leading enterprise local search service used by security and military. In April 2011, Nokia released a beta version of 3D maps. By August 2011, the coverage has expanded to 23 cities, in 2012, Nokia bought EarthMine, which specialises in street level 3D image capture. In May 2011, Ovi Maps was renamed to Nokia Maps. In October 2011, Maps & Drive for Windows Phone 7 was announced, available on Nokia Lumia phones. However, major features such as off-line routing and text-to-speech navigation of street names, compared to the Symbian version, were absent.
These features were brought over to the Windows Phone platform in 2012. On 13 November 2012, Nokia announced that it would rebrand its location offering as HERE to highlight its vision for the future of location-based services and its belief in the importance of mapping. In June 2014, Here announced that it had acquired Medio a Seattle-based start-up that specialized in predictive analytics. In 2014, Windows Phone's low market share, as well as the end of Nokia's partnership with Microsoft, led to the company prioritizing Android and iOS development. Here launched the Here beta app for Samsung Galaxy smartphones in August 2014. In October the app became available on all Android devices running on 4.1 Jelly Bean or higher. The Here app was re-launched for iOS 8 platform on 11 March 2015. On 3 August 2015, Here was sold to a consortium of German car makers Audi, BMW, Mercedes. On 4 December 2015, the consortium completed the acquisition for €2.8 billion. As of December 2015 the company had 6,500 employees.
In December 2016, Tencent and GIC Private Limited agreed to buy a 10% stake in Here. But in September 2017, the offer of the three companies failed, as US authorities did not authorize the transaction. In January 2017 it was reported. In September 2017, Here and Pioneer Corporation have reached an agreement in which HERE would acquire 3% of Pioneer’s stock at a value of €17.3 million. In parallel, at the same cost, Pioneer would acquire less than 1% of Here. In January 2018, Continental and Bosch acquired a 5% stake in Here. In December 2019, Mitsubishi Corporation and Nippon Telegraph and Telephone Corporation of Japan acquired a 30% stake in Here. Upon completion of the transaction, HERE would have nine direct and indirect shareholders: Audi, Bosch, BMW Group, Intel Capital, MC, Mercedes-Benz, NTT and Pioneer. In November 2017, Here announced it would acquire Advanced Telematic Systems for an undisclosed amount; the German consortium together hold a 74% stake in the company. Audi BMW Daimler Intel Bosch Continental Pioneer On 20 December 2019, it was announced that Mitsubishi and NTT together would acquire a 30% stake in the company.
The 2016 Jaguar Cars XF and XJ models incorporate H
Pope Paul I was Bishop of Rome from 29 May 757 to his death in 767. He first served as a Roman deacon and was employed by his brother, Pope Stephen II, in negotiations with the Lombard kings. Paul was a native of Rome, he and his brother Stephen had been educated for the priesthood at the Lateran palace. After Stephen's death on 26 April 757, Paul prevailed over a faction that wanted to make the Archdeacon Theophylact pope and was chosen his brother's successor by the majority that wished a continuation of the late pope's policy; the new pope's reign was dominated by relations with the Frankish and Lombard kings and with the Eastern emperor. He adopted an independent tone in informing the imperial Exarch in Ravenna of his election, but wrote to Pepin the Younger that the Frankish alliance should be maintained unimpaired. Paul was concerned of the danger posed by the Lombard king Desiderius; the Lombards held the cities of Imola, Osimo and Ancona, which were claimed by Rome, in 758 seized upon the duchies of Spoleto and Benevento.
On his return from suppressing a revolt in Benevento, Desiderius visited Rome and compelled Paul to write to Pepin asking him to concede all the Lombard claims. He promised to return Imola, but on condition that the pope should persuade Pepin to send back Lombard hostages held by the Franks. In a letter, to secure the envoys a safe passage through Lombard territory, Paul agreed to the demands of Desiderius and begged Pepin to accede to the wishes of the Lombards by making a treaty of peace and returning the hostages. In a second secret letter, the Paul advised Pepin of the agreement of Desiderius with the Byzantines for the conquest of Ravenna, implored Pepin to come to the aid of the pope, to force the Lombard king to yield the towns retained by him. Pepin found it advisable to maintain good relations with Desiderius, Paul accomplished little by his double-dealing. However, Pepin gave the pope some support and acted as arbiter between the Roman and Lombard claims. In 765, papal privileges were restored in Beneventine and Tuscan territory and in Spoleto.
Meanwhile, the alienation from Constantinople grew greater. Several times in 759, Paul feared that the Eastern Roman Emperor would send an armament against the city of Rome. Paul lived in continual dread lest Eastern Roman ambitions turn the Frankish influence in favor of the Lombards; this was attempted, but Pepin held to his original foreign policy regarding Italy. Paul died in Rome on 28 June 767. Kirsch, J. P.. "Pope Paul I". Catholic Encyclopedia. "Paul. The name of five popes. Paul I". New International Encyclopedia. 1905
For other persons named Charles Brenner, see Charles Brenner. Charles Brenner born October 30, 1961 is the Roy J. Carver Chair of Biochemistry and a director of the Obesity Initiative at the University of Iowa, he is a major contributor to work on nicotinamide adenine dinucleotide metabolism, who discovered the eukaryotic nicotinamide riboside kinase pathway. Brenner is a graduate of Wesleyan University and a veteran of biotechnology companies, having worked at Chiron Corporation and DNAX Research Institute, prior to graduate school at Stanford University School of Medicine. Brenner conducted post-doctoral research at Brandeis University with Gregory Petsko and took his first academic position at Thomas Jefferson University in 1996, moving to Dartmouth Medical School in 2003, where he served as Associate Director for Basic Sciences at Norris Cotton Cancer Center, he was recruited to chair biochemistry at Iowa in 2009. Brenner has made multiple contributions to molecular biology and biochemistry, beginning with purification and characterization of the Kex2 proprotein convertase at Stanford.
He has been funded by agencies including the Leukemia & Lymphoma Society, the March of Dimes, the Burroughs Wellcome Fund, the Beckman Foundation, the Lung Cancer Research Foundation, the National Institutes of Health, the National Science Foundation. Significant research projects include molecular dissection of the function of the FHIT tumor suppressor gene and inhibition of DNA methylation, discovery of new steps in nicotinamide adenine dinucleotide metabolism. Notably, the Brenner laboratory discovered that yeast and humans use nicotinamide riboside to make NAD+, for which Brenner was recognized with a William E. M. Lands lectureship at University of Michigan. In addition to gene discovery and characterization in nicotinamide adenine dinucleotide metabolism, Dr. Brenner developed targeted, quantitative analysis of the NAD+ metabolome and is active in translating NR technologies to treat and prevent human conditions including diabetic and chemotherapeutic peripheral neuropathy, heart failure, central brain injury.
This work includes the first human trial of NR, which demonstrated safe oral availability as an NAD+ precursor. Though Brenner was the first to show that NR increases SIR2 activity and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs metabolic stresses that dysregulate NAD+ and NADPH, he showed that rodent postpartum mothers are under severe metabolic stress to their NAD system and that supplementing such mothers with NR increases maternal weight loss, advances juvenile development and provides long lasting neurodevelopmental advantages into adulthoodBrenner is author of more than 125 publications and was the senior editor of the 2004 book, Oncogenomics: Molecular Approaches to Cancer. ISBN 0-471-22592-4 In 2012, Brenner was asked by the President of the American Society for Biochemistry and Molecular Biology to develop pre-medical curriculum recommendations that would be consistent with a revised MCAT examination.
These recommendations, which include development of inorganic and biochemistry coursework, more geared toward the chemistry of bioorganic functional groups, have been further refined in academic journals. Brenner's work in this area was recognized by the 2016 ASBMB Award for Exemplary Contributions to Education. Brenner is a former member of the Scientific Advisory Board of Sirtris Pharmaceuticals, he is the founder of NRomics and was a co-founder of ProHeathspan prior to its acquisition by ChromaDex, for which he serves as member of the scientific advisory board and chief scientific advisor Charles Brenner and David Duggan Oncogenomics: Molecular Approaches to Cancer. John Wiley & Sons, Hoboken, NJ. ISBN 0-471-22592-4 The Brenner Lab University of Iowa http://twitter.com/charlesmbrenner Brenner twitter profile http://www.llamapodcast.com/charles-brenner/ Interview with Peter Bowes https://blog.bulletproof.com/charles-brenner/ Interview with Dave Asprey https://player.fm/series/the-dr-drew-podcast/ep-333-charles-brenner Interview with Dr. Drew Pinsky https://bengreenfieldfitness.com/podcast/anti-aging-podcasts/new-anti-aging-supplement/ Interview with Ben Greenfield https://www.ihmc.us/stemtalk/episode-81/ Interview on STEM-Talk https://player.fm/series/the-natalie-eva-marie-show/what-is-nad-metabolism-dr-charles-brenner Interview with Eva Marie and Jonathan Coyle